Ftse Mib
34.439,06
-0,06%
DAX
18.666,53
-0,08%
S&P 500
5.313,18
0,12%
NASDAQ
16.868,23
0,40%
Bitcoin
68.080,57
-1,48%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Soligenix Inc (SNGX) Soligenix Inc (SNGX) Notizie

Soligenix Inc

SNGX
0,371
-0,022 (-5,60%)
Ultimo aggiornamento: 17:03:24
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
23/5/202413:30PRNUSSoligenix Encourages Stockholders to Vote "FOR" Reverse..
22/5/202422:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
21/5/202418:35GLOBEPRISM MarketView Highlights Soligenix, Inc. as it Builds on..
21/5/202413:30PRNUSSuVax™ and MarVax™ Thermostable Vaccine Platform to be..
20/5/202413:30PRNUSSoligenix Encourages Stockholders to Vote Prior to Annual..
17/5/202422:25EDGAR2Form 8-K - Current report
17/5/202422:09EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/5/202413:30PRNUSPositive Clinical Results from HyBryte™ Compatibility Study..
15/5/202422:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/5/202422:16EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10/5/202422:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/5/202413:30PRNUSSoligenix Announces Recent Accomplishments And First Quarter..
06/5/202413:30PRNUSSoligenix to Present at Upcoming Conferences
25/4/202413:30PRNUSSoligenix Extends Patent Protection for its Filovirus..
18/4/202414:30PRNUSSoligenix Announces Pricing of $4.75 Million Public Offering
15/4/202413:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
11/4/202413:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
03/4/202413:30PRNUSSoligenix Announces Agreement on the Design of a Second..
15/3/202412:30PRNUSSoligenix Announces Recent Accomplishments and Year End 2023..
08/2/202413:30PRNUSSoligenix Announces Formation of Behçet's Disease Medical..
25/1/202413:30PRNUSSoligenix to Present at The Microcap Conference
08/1/202413:30PRNUSFDA Grants Soligenix "Fast Track" Designation for Dusquetide..
04/1/202413:30PRNUSSoligenix Announces Top-line Results of the Phase 2a Study..
02/1/202413:30PRNUSSoligenix Announces Publication Demonstrating Complete..
22/12/202322:05EDGAR2Form 8-K - Current report
18/12/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
15/12/202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202322:03EDGAR2Form 8-K - Current report
08/12/202323:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202323:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202323:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202323:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202322:05EDGAR2Form S-3/A - Registration statement under Securities Act of..
01/12/202313:30PRNUS"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma"..
30/11/202313:30PRNUSSoligenix Receives FDA IND Clearance for Phase 2 Clinical..
17/11/202322:05EDGAR2Form 8-K - Current report
17/11/202322:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
13/11/202322:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202313:30PRNUSSoligenix Announces Recent Accomplishments And Third Quarter..
20/10/202322:05EDGAR2Form 8-K - Current report
20/10/202322:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
17/10/202319:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
17/10/202319:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/10/202322:45EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
16/10/202313:30PRNUSSoligenix to Present at The ThinkEquity Conference
13/10/202319:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
25/9/202313:30PRNUSSoligenix Announces Achievement of Two-Year Stability with..
Apertura: 0,3856 Min: 0,3668 Max: 0,3876
Chiusura: 0,393

La tua Cronologia

NASDAQ
SNGX
Soligenix
ASX
TRE
Toubani Resources
TG
2S3
APA
BIT
S31945
Societe Generale Effekten
BIT
P1YXC9
NLBNPIT1YXC9 20991231 49...
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network